Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP638656.RA4E_elIFxJtT5HSfn0-oChctKEJnPO1wo-bDdoeIsi6Y130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP638656.RA4E_elIFxJtT5HSfn0-oChctKEJnPO1wo-bDdoeIsi6Y130_assertion type Assertion NP638656.RA4E_elIFxJtT5HSfn0-oChctKEJnPO1wo-bDdoeIsi6Y130_head.
- NP638656.RA4E_elIFxJtT5HSfn0-oChctKEJnPO1wo-bDdoeIsi6Y130_assertion description "[In this study, BPI-ANCA were demonstrated most often in patients with ulcerative colitis (36/92, 39%), Crohn's disease (17/66, 26%) and cystic fibrosis (11/14, 79%), but also in patients with rheumatoid arthritis (8/40, 20%), systemic lupus erythematosus (SLE) (111/65, 17%) and mixed connective tissue disease (4/18, 22%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP638656.RA4E_elIFxJtT5HSfn0-oChctKEJnPO1wo-bDdoeIsi6Y130_provenance.
- NP638656.RA4E_elIFxJtT5HSfn0-oChctKEJnPO1wo-bDdoeIsi6Y130_assertion evidence source_evidence_literature NP638656.RA4E_elIFxJtT5HSfn0-oChctKEJnPO1wo-bDdoeIsi6Y130_provenance.
- NP638656.RA4E_elIFxJtT5HSfn0-oChctKEJnPO1wo-bDdoeIsi6Y130_assertion SIO_000772 10836522 NP638656.RA4E_elIFxJtT5HSfn0-oChctKEJnPO1wo-bDdoeIsi6Y130_provenance.
- NP638656.RA4E_elIFxJtT5HSfn0-oChctKEJnPO1wo-bDdoeIsi6Y130_assertion wasDerivedFrom befree-20140225 NP638656.RA4E_elIFxJtT5HSfn0-oChctKEJnPO1wo-bDdoeIsi6Y130_provenance.
- NP638656.RA4E_elIFxJtT5HSfn0-oChctKEJnPO1wo-bDdoeIsi6Y130_assertion wasGeneratedBy ECO_0000203 NP638656.RA4E_elIFxJtT5HSfn0-oChctKEJnPO1wo-bDdoeIsi6Y130_provenance.